Cargando…

Potential Prognostic Markers for Relapsed/Refractory vs. Responsive Acute Myeloid Leukemia

SIMPLE SUMMARY: Acute myeloid leukemia (AML) is the most common blood cancer in the elderly, which progresses rapidly and is often fatal. The prognosis for AML remains poor in most older patients: only about 15% of patients over 60 years of age can recover. Our aim is to determine new potential AML...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitkevičienė, Aida, Skliutė, Giedrė, Žučenka, Andrius, Borutinskaitė, Veronika, Navakauskienė, Rūta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179343/ https://www.ncbi.nlm.nih.gov/pubmed/35681732 http://dx.doi.org/10.3390/cancers14112752

Ejemplares similares

Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling
por: Valiulienė, Giedrė, et al.
Publicado: (2021)

HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia
por: Vitkevičienė, Aida, et al.
Publicado: (2019)

Corrigendum to “HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia”
por: Vitkevičienė, Aida, et al.
Publicado: (2020)

Genetic and Epigenetic Signatures in Acute Promyelocytic Leukemia Treatment and Molecular Remission
por: Borutinskaitė, Veronika, et al.
Publicado: (2022)

Menstrual Blood-Derived Endometrial Stem Cells’ Impact for the Treatment Perspective of Female Infertility
por: Skliutė, Giedrė, et al.
Publicado: (2021)

The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming
por: Borutinskaitė, Veronika, et al.
Publicado: (2015)

Effects of human placenta cryopreservation on molecular characteristics of placental mesenchymal stromal cells
por: Navakauskienė, Rūta, et al.
Publicado: (2023)

Characterization of Epigenetic and Molecular Factors in Endometrium of Females with Infertility
por: Skliutė, Giedrė, et al.
Publicado: (2022)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020)

Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells
por: Savickiene, Jurate, et al.
Publicado: (2012)

Prognostic Gene Predictors of Gestational Diabetes in Endometrium and Follicular Fluid of Women after Infertility
por: Vaigauskaitė, Brigita, et al.
Publicado: (2022)

Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
por: Zucenka, Andrius, et al.
Publicado: (2021)

The Effects of the Follicle-Stimulating Hormone on Human Follicular Fluid-Derived Stromal Cells
por: Skliutė, Giedrė, et al.
Publicado: (2023)

Decidualization Potency and Epigenetic Changes in Human Endometrial Origin Stem Cells During Propagation
por: Valatkaitė, Elvina, et al.
Publicado: (2021)

Small Molecule Treatments Improve Differentiation Potential of Human Amniotic Fluid Stem Cells
por: Zentelytė, Aistė, et al.
Publicado: (2021)

Epigenetic changes during hematopoietic cell granulocytic differentiation – comparative analysis of primary CD34+ cells, KG1 myeloid cells and mature neutrophils
por: Navakauskienė, Rūta, et al.
Publicado: (2014)

Metabolic Profile and Neurogenic Potential of Human Amniotic Fluid Stem Cells From Normal vs. Fetus-Affected Gestations
por: Valiulienė, Giedrė, et al.
Publicado: (2021)

Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement
por: Dapkevičiūtė-Purlienė, Austėja, et al.
Publicado: (2023)

Treatment for Relapsed/Refractory Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2021)

Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia
por: Goswami, Meghali, et al.
Publicado: (2022)

Human endometrium-derived mesenchymal stem/stromal cells application in endometrial-factor induced infertility
por: Bausyte, Raminta, et al.
Publicado: (2023)

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
por: Ramos, Nestor R., et al.
Publicado: (2015)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Effect of 3D Spheroid Culturing on NF-κB Signaling Pathway and Neurogenic Potential in Human Amniotic Fluid Stem Cells
por: Valiulienė, Giedrė, et al.
Publicado: (2023)

FLT4 as a marker for predicting prognostic risk of refractory acute myeloid leukemia
por: Lee, Ji Yoon, et al.
Publicado: (2023)

B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia
por: Goswami, Meghali, et al.
Publicado: (2020)

Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
por: Popescu, Bogdan, et al.
Publicado: (2019)

Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia
por: Ma, Jiale, et al.
Publicado: (2021)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA
por: Žučenka, Andrius, et al.
Publicado: (2023)

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia
por: Roboz, Gail J., et al.
Publicado: (2017)

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
por: Kang, Dongwoo, et al.
Publicado: (2021)

Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
por: Raghuram, Nikhil, et al.
Publicado: (2023)

The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China
por: Gu, Mianmian, et al.
Publicado: (2019)

Radiopharmaceuticals for Relapsed or Refractory Leukemias
por: Kunos, Charles A., et al.
Publicado: (2019)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
por: Chew, Serena, et al.
Publicado: (2020)

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020)

Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
por: Labrador, Jorge, et al.
Publicado: (2022)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cenj6lrjde015imaj5p6d35hr3